Compare MMA & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMA | CALC |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 11.2M |
| IPO Year | 2023 | 2020 |
| Metric | MMA | CALC |
|---|---|---|
| Price | $0.39 | $0.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 81.6K | ★ 285.9K |
| Earning Date | 05-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.46 |
| 52 Week High | $2.00 | $7.20 |
| Indicator | MMA | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 33.44 | 47.84 |
| Support Level | $0.35 | $0.52 |
| Resistance Level | $0.50 | $0.77 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.09 | 30.50 |
MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.